APA সাইটেশন

Morgensztern, D. (2019). KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1–49%. J Thorac Dis.

শিকাগো স্টাইলে সাইটেশন

Morgensztern, Daniel. "KEYNOTE-042 and the Role for Single Agent Pembrolizumab in Patients With PD-L1 Tumor Proportion Score 1–49%." J Thorac Dis 2019.

এমএলএ সাইটেশন

Morgensztern, Daniel. "KEYNOTE-042 and the Role for Single Agent Pembrolizumab in Patients With PD-L1 Tumor Proportion Score 1–49%." J Thorac Dis 2019.